Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual‐dose proton pump inhibitor: Acotiamide plus usual‐dose proton pump inhibitor <i>versus</i> double‐dose proton pump inhibitor

Takeuchi, Toshihisa; Takahashi, Yoshiaki; Kawaguchi, Shinpei; K, Ota; Harada, Satoshi; Kojima, Yuichi; Sakamoto, Hiroki; Kuramoto, Takanori; Kojima, Kensuke; Sanomura, Makoto; Hoshimoto, Masahiro; Higashino, Takeshi; Itabashi, Takeshi; Takada, Kiyoshi; Sakaguchi, Masahiro; Tominaga, Kazunari; Kusano, Motoyasu; Higuchi, Kazuhide

doi:10.1111/jgh.13970

Cited by 19 publications

(13 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, many doctors use the revised FSSG to diagnose FD and evaluate the effects of FD treatment in daily medical care. 26,50 On the other hand, there are limited reports on the use of the modified FSSG in placebo-controlled double-blind controlled trials in patients with FD, 51 and further verification is necessary. Even in our hospital, the modified FSSG is widely used in GERD and FD medical care; however, in conducting clinical research, we do not fully verify the validity of question contents and responsiveness to treatment.…”

Section: Discussionmentioning

confidence: 99%

“…26,50 On the other hand, there are limited reports on the use of the modified FSSG in placebo-controlled double-blind controlled trials in patients with FD, 51 and further verification is necessary. In addition, many doctors use the revised FSSG to diagnose FD and evaluate the effects of FD treatment in daily medical care.…”

Section: Modified Fssg Scores After Treatment Amentioning

confidence: 99%

See 1 more Smart Citation

Effects of acotiamide on functional dyspepsia patients with heartburn who failed proton pump inhibitor treatment in Japanese patients: A randomized, double‐blind, placebo‐controlled crossover study

Funaki

Ogasawara

Kawamura

et al. 2019

Neurogastroenterology Motil

View full text Add to dashboard Cite

Background: Functional dyspepsia (FD) and non-erosive reflux disease (NERD) are gastrointestinal disorders that often overlap. In this randomized, double-blind, placebo-controlled crossover study, the effects of adding acotiamide to treatment with proton pump inhibitors (PPI) were investigated in FD patients with heartburn who failed PPI treatment, corresponding to PPI-resistant NERD. Methods:The subjects included 16 FD patients with heartburn who failed PPI treatment, and they were administered acotiamide or a placebo for 28 days. After suspending medication for 28 days, the trial drug and placebo were crossed over and administered for 28 days. Before the study began and after each administration period, high-resolution impedance manometry (HRiM) was performed, and the modified frequency scale for the symptoms of gastroesophageal reflux disease (FSSG) questionnaire was administered.Key Results: Postprandial fullness in the FD assessment and all modified FSSG items were significantly lower in the acotiamide group than in the placebo group.Esophagogastric junction pressure was significantly higher in the acotiamide group.The distal contractile integral (DCI) pressure and the highest DCI pressure both increased significantly in the acotiamide group. Moreover, in the acotiamide group, the frequency of abnormal primary peristalsis decreased to normal levels; complete bolus transit (CBT), an indicator of esophageal clearance, increased; and CBT time decreased. Conclusions & Inferences:Acotiamide was considered to improve upper gastrointestinal functions not only in the stomach but also in the esophagus. Adding acotiamide to PPI therapy appears to improve upper abdominal symptoms in FD patients with heartburn who failed PPI treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Modified Fssg Scores After Treatment Amentioning

confidence: 99%

Effects of acotiamide on functional dyspepsia patients with heartburn who failed proton pump inhibitor treatment in Japanese patients: A randomized, double‐blind, placebo‐controlled crossover study

Funaki

Ogasawara

Kawamura

et al. 2019

Neurogastroenterology Motil

View full text Add to dashboard Cite

show abstract

“…2A). [37][38][39][40] Vonoprazan seems to be effective for PPI-resistant reflux esophagitis. 41 Twenty-four PPIresistant reflux esophagitis patients were enrolled in this study and 58.3% had severe erosive esophagitis.…”

Section: Gastroesophageal Reflux Diseasementioning

confidence: 99%

Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker

Mori

Suzuki

2019

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Proton pump inhibitors are commonly utilized for the treatment of gastric acid-related diseases, such as gastroesophageal reflux disease, peptic ulcer disease, and Helicobacter pylori infection, and for the prevention of low-dose aspirin or nonsteroidal anti-inflammatory drug-induced peptic ulcers. Vonoprazan is a first-in-class potassium-competitive acid blocker, which has distinct advantages compared to other conventional proton pump inhibitors in terms of the efficacy for acid suppression. Due to its strong gastric acid suppression capabilities, vonoprazan serves as an effective drug for the treatment of gastroesophageal reflux disease and H. pylori infection.

show abstract

“…(4) improvement of symptoms was observed within 3 months after starting acotiamide; (5) acotiamide therapy was ceased; (6) Helicobacter pylori-negative patients, and (7) the patient visited the clinic at least once after cessation and completed the Izumo scale score questionnaire. Based on these criteria, 139/209 patients were excluded for the following reasons: no cessation of acotiamide therapy (n = 62), < 3-months follow-up (n = 51), no improvement of dyspepsia symptoms within 3 months (n = 13), and < 1-month acotiamide intake because of poor compliance (n = 13).…”

Section: Inclusion and Exclusion Criteriamentioning

confidence: 99%

“…The Izumo scale, a self-reported questionnaire to score abdominal symptom-related quality of life, has been broadly used and validated [7][8][9][10][11] (Fig. 1).…”

Section: Evaluating Abdominal Symptoms Using the Izumo Scalementioning

confidence: 99%

Timing and Predictors of Recurrence of Dyspepsia Symptoms after Cessation of Acotiamide Therapy for Functional Dyspepsia: A Long-Term Observational Study

et al. 2019

View full text Add to dashboard Cite

Background/Aims: The long-term outcomes of patients after cessation of acotiamide therapy in patients with functional dyspepsia remains unclear. The aim of this study is to investigate the timing and predictors of recurrence of dyspepsia symptoms after cessation of acotiamide therapy for functional dyspepsia. Methods: Seventy patients treated with acotiamide for functional dyspepsia who then ceased treatment were enrolled. Changes in dyspepsia symptoms were evaluated using the Izumo scale, a self-reporting questionnaire of abdominal symptom-related quality of life. Patients were subclassified into epigastric pain, postprandial distress, and overlapped types. Results: The mean follow-up after cessation of acotiamide was 1.9 years. After cessation of acotiamide, 39 patients (56%) had recurrence. Kaplan-Meier analysis revealed a recurrence-free rate of 51% at 1 year. Predictors of recurrence evaluated with a Cox proportional hazards model showed that overlapped-type dyspepsia and consultation with the treating physician before cessation were identified as significant positive and negative predictors, respectively (p < 0.05). The resumption of acotiamide significantly decreased the score for dyspepsia symptoms at 1 month. Conclusions: Dyspepsia symptoms recur about one year after cessation of acotiamide therapy. Patients with overlapped-type dyspepsia should be carefully followed after cessation. Patients should consult their treating physician before stopping acotiamide.

show abstract

Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual‐dose proton pump inhibitor: Acotiamide plus usual‐dose proton pump inhibitor versus double‐dose proton pump inhibitor

Cited by 19 publications

References 40 publications

Effects of acotiamide on functional dyspepsia patients with heartburn who failed proton pump inhibitor treatment in Japanese patients: A randomized, double‐blind, placebo‐controlled crossover study

Effects of acotiamide on functional dyspepsia patients with heartburn who failed proton pump inhibitor treatment in Japanese patients: A randomized, double‐blind, placebo‐controlled crossover study

Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker

Timing and Predictors of Recurrence of Dyspepsia Symptoms after Cessation of Acotiamide Therapy for Functional Dyspepsia: A Long-Term Observational Study

Contact Info

Product

Resources

About